<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688528</url>
  </required_header>
  <id_info>
    <org_study_id>S63909</org_study_id>
    <secondary_id>FAF-C/2018/1266</secondary_id>
    <nct_id>NCT04688528</nct_id>
  </id_info>
  <brief_title>Dose De-escalation and Sentinel Lymph Node Mapping Driven Radiotherapy of Contralateral Neck in cN1-2 HNSCC</brief_title>
  <acronym>SEMIRAHN</acronym>
  <official_title>A Prospective Randomized Phase 2 Study of Dose and Volume De-escalation Radiotherapy With Sentinel Lymph Nodes Mapping for Contralateral Irradiation in Unilaterally Node Positive Head and Neck Squamous Cell Carcinomas (SEMIRAHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting tegen Kanker</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves head and neck squamous cell carcinomas (HNSCC) of the oral cavity,&#xD;
      oropharynx, larynx or hypopharynx with positive nodes on only one side of the neck and no&#xD;
      distant metastasis treated by primary (chemo)radiotherapy.&#xD;
&#xD;
      The elective node irradiation on the contralateral side is not always mandatory and the dose&#xD;
      may be too high. In this study, we evaluate two strategies: the impact of sentinel lymph node&#xD;
      mapping to tailor the volumes to irradiate and the dose reduction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risk of lymph drainage to the contralateral side of the neck is limited to maximum 50% of&#xD;
      the patients. Moreover, the risk of occult metastases lies between 20 and 40%. As a&#xD;
      consequence, the rule of irradiating the contralateral neck with a prophylactic intent&#xD;
      (&quot;elective nodal irradiation&quot;) in nearly all HNSCC patients roughly doubles the irradiated&#xD;
      volume and, hence, increases the risk of developing more frequent and more severe acute and&#xD;
      late side effects. The use of sentinel lymph node mapping to assess the contralateral side of&#xD;
      the neck should help to determine the individual drainage to the contralateral side of the&#xD;
      neck and, in case of drainage, determine which nodes need to be irradiated. The ultimate goal&#xD;
      is to reduce the volume irradiated at prophylactic dose to decrease the risk of severe late&#xD;
      side effects (volume de-escalation strategy). This strategy is proposed based on the recent&#xD;
      completion of a similar study led by the coordinating investigator, together with the head&#xD;
      and neck team of the CHU-UCL-Namur, in HNSCC patients without macroscopic nodes in the neck&#xD;
      and treated with (chemo)radiotherapy. It was shown that sentinel lymph node mapping helped to&#xD;
      safely individualize and de-escalate the elective nodal irradiation volume and significantly&#xD;
      reduce the risk of severe late side effects. Anyway, it is unknown if the whole sub-region of&#xD;
      the neck containing the sentinel lymph node(s) or the node(s) only should be defined as&#xD;
      target volume.&#xD;
&#xD;
      Moreover, the dose used nowadays for elective nodal irradiation, i.e. 50 Gy in fractions of 2&#xD;
      Gy or biologically equivalent, dates back from the 70's. Many arguments (a.o. our better&#xD;
      capacity to stage the neck with 3D imaging and the use of concomitant chemotherapy in the&#xD;
      majority of node-positive HNSCC) are in favour of dose de-escalation. A multicentric&#xD;
      randomized study performed in 100 HNSCC recently showed that the elective dose could be&#xD;
      reduced to 40 Gy in fractions of 2 Gy or biologically equivalent, helping to reduce the risk&#xD;
      of late dysphagia at 6 months post-radiotherapy. Confirmatory studies need to be performed on&#xD;
      larger groups of patients.&#xD;
&#xD;
      The primary aim is to evaluate contralateral regional control (cRC) rate at 2 years in head&#xD;
      and neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, larynx or&#xD;
      hypopharynx with positive nodes on only one side of the neck and no distant metastasis&#xD;
      treated by (chemo)radiotherapy applying a dose- and/or volume de-escalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contralateral regional control (cRC) rate at 2 years</measure>
    <time_frame>From baseline to 2 years after radiotherapy</time_frame>
    <description>The rate of tumor control in the draining nodal regions of the neck.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire assessing the quality of life of patients with head and neck cancer</measure>
    <time_frame>From baseline to every 2 months in the first year and every 3 months in the second year after radiotherapy.</time_frame>
    <description>Measured by the EORTC QLQ-H&amp;N35 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire assessing the quality of life of cancer patients.</measure>
    <time_frame>From baseline to every 2 months in the first year and every 3 months in the second year after radiotherapy.</time_frame>
    <description>Measured by the EORTC QOL-C30 (version3) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal tissue complication probability (NTCP) gain estimation</measure>
    <time_frame>Time from RT up to 2 years after RT.</time_frame>
    <description>Estimation of the difference in risk of complications for xerostomia, dysphagia and hypothyroidism according to validated NTCP models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Control</measure>
    <time_frame>Time from RT until local progression or death whichever comes first, up to 2 years after RT.</time_frame>
    <description>Loco-regional control (LRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from RT until the occurrence of a new tumor or death whichever comes first, up to 2 years after RT.</time_frame>
    <description>Cancer specific survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from RT until death from any cause</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>Time from start of RT up to 2 years after RT</time_frame>
    <description>Acute and Late Toxicity Scoring</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm A: Unilateral RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If SPECT/CT shows ipsilateral drainage and the tumor does not cross the midline, the subject will automatically be assigned to Arm A, and will receive ipsilateral Radiotherapy with reduced prophylactic dose outside of the macroscopically involved nodes. The contralateral side of the neck will be spared according to the absence of sentinel lymph node drainage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Whole level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.&#xD;
Arm B 'Whole Level': on the contralateral side of the neck, the whole level(s) containing the draining sentinel lymph node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: SLN alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.&#xD;
Arm C 'SLN alone': on the contralateral side of the neck, only the sentinel node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dose de-escalation and / or Volume de-escalation</intervention_name>
    <description>The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.</description>
    <arm_group_label>Arm A: Unilateral RT</arm_group_label>
    <arm_group_label>Arm B: Whole level</arm_group_label>
    <arm_group_label>Arm C: SLN alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent given according to ICH/GCP and national/local regulations&#xD;
             must be obtained prior to any screening procedures.&#xD;
&#xD;
          2. World Health Organization (WHO) performance status 0-1.&#xD;
&#xD;
          3. Age ≥ 18 years.&#xD;
&#xD;
          4. Patients with a pathologically proven invasive HNSCC, including oral cavity,&#xD;
             oropharynx (independently of HPV status), larynx or hypopharynx.&#xD;
&#xD;
          5. Decision by Multidisciplinary Tumor Board of primary treatment with radical&#xD;
             radiotherapy with or without concurrent chemotherapy (according to the local&#xD;
             guidelines).&#xD;
&#xD;
          6. Baseline imaging of the neck:&#xD;
&#xD;
               -  a. ≤ 2.5 mm slices CT with iodine injection (independently or during the&#xD;
                  FDG-PET/CT examination IF acquired in normal diagnostic conditions, i.e. arms&#xD;
                  along the thorax with diagnostic quality);&#xD;
&#xD;
               -  b. MRI not mandatory but allowed, performed according to centres guidelines;&#xD;
&#xD;
               -  c. FDG-PET/CT.&#xD;
&#xD;
          7. Tumor characteristics:&#xD;
&#xD;
               1. cT-classification (8th TNM staging): T1(except T1 of glottis)-T3.&#xD;
&#xD;
               2. cN-classification (8th TNM staging), as assessed by iodine contrasted CT (or MRI)&#xD;
                  and FDG-PET:&#xD;
&#xD;
             i. mandatorily cN0 contralaterally to the primary tumor (or on one side of the neck&#xD;
             for midline primary tumors):&#xD;
&#xD;
        1. smallest diameter &lt; 5 mm in retropharyngeal level (VIIa); 2. smallest diameter of&#xD;
        Küttner node (level IIa) &lt; 12 mm; 3. smallest diameter &lt; 10 mm or sum of smallest and&#xD;
        largest diameters &lt; 17 mm in any other level; 4. no central necrosis ; 5. maximal&#xD;
        standardized uptake value (SUVmax) ≤ 2.2; 6. in dubious cases (typically 2.2 &lt; SUVmax &lt; 4.5&#xD;
        and inconclusive CT or MRI), US-guided FNAC may be required to exclude positive node&#xD;
        contralaterally.&#xD;
&#xD;
        ii. ipsilaterally positive (if any of the above mentioned criteria is met). c. No distant&#xD;
        metastasis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has history of:&#xD;
&#xD;
               1. radiotherapy or surgery in the neck with potential impact on lymphatic drainage&#xD;
                  (&quot;violated neck&quot;);&#xD;
&#xD;
               2. cancer in the last five years (excluding skin basal cell carcinoma and in situ&#xD;
                  cervix carcinoma);&#xD;
&#xD;
               3. Absolute contra-indication to iodine contrast injection, even after proper&#xD;
                  cortisone and cetirizine pre-medication.&#xD;
&#xD;
          2. HNSCC from nose, sinuses, oesophagus, salivary glands or nasopharynx.&#xD;
&#xD;
          3. Non-HNSCC histology.&#xD;
&#xD;
          4. Positive contralateral neck by node size or positive US-FNAC in dubious nodes.&#xD;
&#xD;
          5. Synchronous second malignancy.&#xD;
&#xD;
          6. Distant metastasis.&#xD;
&#xD;
          7. Tumor crossing the midline without contralateral mapping after 99mTc-nanocolloïd&#xD;
             injection.&#xD;
&#xD;
          8. Any psychological disorder or familial, sociological or geographical condition which,&#xD;
             in the investigator's opinion, might jeopardise participant's safety or compliance&#xD;
             with the protocol.&#xD;
&#xD;
          9. Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             child-bearing potential and not using an adequate contraceptive method.&#xD;
&#xD;
        Highly effective methods of birth control are defined as those, alone or in combination,&#xD;
        that result in a low failure rate (i.e., less than 1% per year) when used consistently and&#xD;
        correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true&#xD;
        sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period&#xD;
        of risk associated with the Trial treatments) or vasectomised partner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François Daisne, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François Daisne, MD, PhD</last_name>
    <phone>+32-16-34-76-00</phone>
    <email>jean-francois.daisne@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Bruyninckx, BA</last_name>
    <phone>+32-16-34-76-00</phone>
    <email>chris.bruyninckx@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clémence Al Wardi</last_name>
      <email>clemence.alwardi@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Dirk Van Gestel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Duprez</last_name>
      <email>frederic.duprez@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Frederic Duprez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Bruyninckx</last_name>
      <email>chris.bruyninckx@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Rita Aerts</last_name>
      <email>rita.aerts@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-François Daisne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Nuyts, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-UCL Namur</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Gilsoul</last_name>
      <email>monique.gilsoul@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Deheneffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges Lawson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Daisne JF, Installé J, Bihin B, Laloux M, Vander Borght T, Mathieu I, Lawson G. SPECT/CT lymphoscintigraphy of sentinel node(s) for superselective prophylactic irradiation of the neck in cN0 head and neck cancer patients: a prospective phase I feasibility study. Radiat Oncol. 2014 May 28;9:121. doi: 10.1186/1748-717X-9-121.</citation>
    <PMID>24885222</PMID>
  </reference>
  <results_reference>
    <citation>Longton E, Lawson G, Bihin B, Mathieu I, Hanin FX, Deheneffe S, Vander Borght T, Laloux M, Daisne JF. Individualized Prophylactic Neck Irradiation in Patients with cN0 Head and Neck Cancer Based on Sentinel Lymph Node(s) Identification: Definitive Results of a Prospective Phase 1-2 Study. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):652-661. doi: 10.1016/j.ijrobp.2020.03.021. Epub 2020 Apr 12.</citation>
    <PMID>32294522</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>Dose and Volume de-escalation in radiotherapy</keyword>
  <keyword>sentinel lymph nodes mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

